20251123-东吴证券-医药生物行业跟踪周报_药店现金流稳健_估值低_重点推荐益丰药房_大参林等_26页_1mb

Industry Performance Overview

The pharmaceutical industry experienced significant declines this week and year-to-date, with the A-share index falling -6.9% and outperforming the CSI 300 by -0.5 percentage points year-to-date. Sub-sectors such as medical devices, traditional Chinese medicine, and pharmaceutical commercialization saw large losses, while stocks like those in Hainan pharmaceutical companies showed gains. Valuations are generally low, with the overall PE at around 21.5 times, offering good value.

Drugstore Sector Turnaround

The drugstore industry is at a turning point, with store closures reducing for the fourth quarter of 2024 and beyond. Key companies like Yifeng Drugstore and Dashenlin have improved performance through cost efficiency and store reformatting, achieving positive margin improvements. Valuations are attractive, with PE under 20 for leaders, indicating a strong position in the competitive landscape.

Innovation Drugs and Research Progress

Recent developments include approvals for drugs like Pfizer's Matabicimab for hemophilia and Merck's sotatercept for heart failure. Clinical trials are advancing for various drugs, such as Bei Tian Tian Heng's EGFR×HER3 dual-antibody ADC. Focus areas include innovation drugs, CXO services, and GLP1 therapies, with companies like BSLI, Bei Jisi, and FedPharma making notable progress.

Investment Outlook

Recommendations prioritize innovation drugs, CXO services, and specific stocks like Yifeng Drugstore, Dashenlin, and Bei Tian Tian Heng. The sector is expected to grow in research and development, with AI pharmaceutical approaches like Jiang Tai Holdings gaining attention.

Key Risks

Potential for unexpected price cuts on drugs or medical devices, stricter healthcare policies affecting reimbursement, and delays in product sales or clinical trial results could impact performance.